JG
Therapeutic Areas
Selvita Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SEL24 (MEN1703) | Acute Myeloid Leukemia (AML) | Phase 1/2 |
| SEL120 | Acute Myeloid Leukemia (AML) & High-Risk Myelodysplastic Syndrome (HR-MDS) | Phase 1b |
| SEL201 | Solid Tumors | Pre-clinical |
| SEL313 | Solid Tumors | Discovery |
| SEL340 | MTAP-deleted Cancers | Discovery |
Leadership Team at Selvita
BS
Bogusław Sieczkowski
Chief Executive Officer (CEO), Co-founder
PP
Paweł Przewięźlikowski
Chief Operating Officer (COO), Co-founder
KB
Krzysztof Brzózka
Chief Scientific Officer (CSO)
MN
Mirosław Nowakowski
Chief Financial Officer (CFO)
MW
Michał Walczak
Chief Business Officer (CBO)
NP
Natalia Piętka
Vice President, Biology
JK
Jacek Kotański
Vice President, Medicinal Chemistry
CB
Christophe Bourdon
Chief Executive Officer, Selvita France
MB
Michał Bajor
Member of the Management Board, Corporate Development Director
MW
Michał Wójcik
Member of the Supervisory Board, Chairman